Psyence Biomedical Ltd. (PBM) Cash Flow Statement
Where PBM’s cash came from and went, FY2026
March 31, 2026 · U.S. dollars- Cash from operations
- −$8.1M
- Capital expenditures
- $500,229
- Free cash flow
- −$8.6M
- Returned to shareholders
- —
- Change in cash
- $1.3M cash at year-end $7.4M
Drawn to scale: where the cash came from and how it was used. Hover for values.
PBM operating cash flow, capex and free cash flow
PBM cash flow trends, FY2023–FY2026
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$2,153FY2023 | −$8.1MFY2026 | — | |
| Capital expenditures | $0FY2023 | $500,229FY2026 | — | |
| Free cash flow | −$519,603FY2023 | −$8.6MFY2026 | — | |
| Stock-based compensation | $221,287FY2023 | $155,341FY2026 | −11.1%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
PBM cash flow by activity
PBM net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
PBM cash flow statement
| FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Operating activities | ||||
| Net income | −$6.9M | $1.0M | −$51.2M | −$24,489 |
| Depreciation & amortization | $5,266 | $4,268 | $240 | $0 |
| Stock-based compensation | $155,341 | $0 | $317,882 | $221,287 |
| Change in working capital | −$1.2M | −$386,203 | −$1.2M | −$54,437 |
| Other non-cash items | −$151,160 | −$4.4M | $49.1M | −$144,514 |
| Cash from operating activities | −$8.1M | −$3.7M | −$2.9M | −$2,153 |
| Investing activities | ||||
| Capital expenditures | −$500,229 | −$9,877 | −$5,727 | $0 |
| Investments (net) | — | −$16,230 | −$5,727 | $0 |
| Acquisitions & other investing | −$4.0M | $9,877 | $5,727 | — |
| Cash from investing activities | −$4.5M | −$16,230 | −$5,727 | — |
| Financing activities | ||||
| Net borrowing (repayment) | $14.0M | $7.4M | $2.4M | $0 |
| Shares issued | $0 | $1.7M | $0 | $0 |
| Other financing | $0 | $0 | $0 | $1,586 |
| Cash from financing activities | $14.0M | $9.2M | $2.4M | $1,586 |
| Summary | ||||
| Net change in cash | $1.3M | $5.4M | −$601,092 | −$565 |
| Cash at end of period | $7.4M | $6.1M | $733,188 | $1,804 |
| Free cash flow | −$8.6M | −$3.7M | −$3.0M | −$519,603 |
| Operating cash flow / net income | — | −3.69 | — | — |
| Dec '23 | Jun '23 | Mar '23 | Dec '22 | Sep '22 | Jun '22 | Mar '22 | Dec '21 | Sep '21 | |
|---|---|---|---|---|---|---|---|---|---|
| Operating activities | |||||||||
| Net income | −$24,763 | −$62,842 | −$33,122 | $2.3M | $766,838 | $2.0M | $3.0M | $8.3M | −$45,057 |
| Depreciation & amortization | $165 | — | — | — | — | — | — | — | — |
| Stock-based compensation | $159 | — | — | — | — | — | — | — | — |
| Change in working capital | −$167 | −$671,983 | $989,184 | −$404,142 | $71,194 | $167,986 | $110,525 | −$564,885 | $45,000 |
| Other non-cash items | $23,944 | $483,400 | −$1.5M | −$1.9M | −$929,971 | −$2.3M | −$3.3M | −$8.6M | −$6,827 |
| Cash from operating activities | −$662 | −$251,425 | −$550,221 | −$86,258 | −$91,939 | −$125,030 | −$216,377 | −$819,680 | −$6,884 |
| Investing activities | |||||||||
| Capital expenditures | −$4 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Acquisitions & other investing | $0 | −$247,500 | $242.9M | — | — | — | — | −$255.0M | — |
| Cash from investing activities | −$4 | −$247,500 | $242.9M | — | — | — | — | −$255.0M | — |
| Financing activities | |||||||||
| Share repurchases & issuance (net) | — | — | −$243.1M | — | — | — | — | — | — |
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other financing | $738 | $492,770 | $685,000 | $1,452 | — | — | — | $256.5M | $6,827 |
| Cash from financing activities | $738 | $492,770 | −$242.4M | $1,452 | — | — | — | $256.5M | $6,827 |
| Summary | |||||||||
| Net change in cash | $73 | −$6,154 | −$112,721 | −$86,259 | −$91,939 | −$125,030 | −$216,377 | $638,368 | −$57 |
| Cash at end of period | $73 | $9,802 | $15,956 | $128,677 | $214,936 | $306,875 | $431,905 | $648,282 | $9,914 |
| Free cash flow | −$665 | −$251,425 | −$550,221 | −$86,258 | −$91,939 | −$125,030 | −$216,377 | −$819,680 | −$6,884 |
| Operating cash flow / net income | — | — | — | −0.04 | −0.12 | −0.06 | −0.07 | −0.10 | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
PBM cash generation
In fiscal 2026 (ended March 31, 2026), Psyence Biomedical Ltd. generated -$8.1 million of cash from operations and spent $0.5 million on capital expenditures, leaving free cash flow of -$8.6 million. Cash and equivalents rose by $1.3 million over the year.
Related: PBM income statement, PBM balance sheet. See the PBM stock overview for the latest quote and news.
PBM cash flow FAQ
What is Psyence Biomedical Ltd.'s free cash flow?
Psyence Biomedical Ltd.'s free cash flow was -$8.6 million in fiscal 2026: -$8.1 million of operating cash flow minus $0.5 million of capital expenditures It was -$3.7 million a year earlier..
How much cash does Psyence Biomedical Ltd. generate from operations?
Psyence Biomedical Ltd. generated -$8.1 million of cash from operating activities in fiscal 2026.
How much does Psyence Biomedical Ltd. spend on capital expenditures?
Psyence Biomedical Ltd. spent $0.5 million on capital expenditures in fiscal 2026, compared with $0.0 million the year before.